 Christopher Striebich
Concepts (161)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arthritis, Rheumatoid | 14 | 2026 | 1184 | 1.130 |
Why?
| | Antirheumatic Agents | 4 | 2026 | 306 | 0.660 |
Why?
| | Hydroxychloroquine | 2 | 2026 | 65 | 0.460 |
Why?
| | Anti-Citrullinated Protein Antibodies | 3 | 2026 | 125 | 0.380 |
Why?
| | Susac Syndrome | 1 | 2011 | 3 | 0.350 |
Why?
| | Pregnancy Complications, Cardiovascular | 1 | 2011 | 83 | 0.330 |
Why?
| | Interferon-alpha | 2 | 2021 | 195 | 0.260 |
Why?
| | Rheumatoid Factor | 4 | 2022 | 176 | 0.260 |
Why?
| | Lupus Erythematosus, Systemic | 2 | 2025 | 231 | 0.260 |
Why?
| | Autoantibodies | 6 | 2023 | 1466 | 0.250 |
Why?
| | Endothelium, Vascular | 1 | 2011 | 943 | 0.210 |
Why?
| | Meniscus | 1 | 2023 | 23 | 0.190 |
Why?
| | Rheumatology | 1 | 2023 | 116 | 0.190 |
Why?
| | Autoimmune Diseases | 2 | 2019 | 463 | 0.170 |
Why?
| | Anterior Cruciate Ligament Injuries | 1 | 2023 | 162 | 0.170 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 2 | 2002 | 334 | 0.170 |
Why?
| | STAT1 Transcription Factor | 1 | 2021 | 71 | 0.170 |
Why?
| | Lovastatin | 1 | 2020 | 37 | 0.160 |
Why?
| | Methotrexate | 2 | 2021 | 255 | 0.160 |
Why?
| | Osteoarthritis, Knee | 1 | 2023 | 270 | 0.150 |
Why?
| | STAT3 Transcription Factor | 1 | 2021 | 211 | 0.150 |
Why?
| | Interleukin-10 | 1 | 2021 | 305 | 0.150 |
Why?
| | Synovial Fluid | 1 | 1998 | 72 | 0.140 |
Why?
| | Rheumatic Diseases | 1 | 2019 | 93 | 0.140 |
Why?
| | C-Reactive Protein | 1 | 2020 | 416 | 0.140 |
Why?
| | Arthroplasty, Replacement, Knee | 1 | 2023 | 372 | 0.140 |
Why?
| | B-Lymphocytes | 3 | 2012 | 857 | 0.130 |
Why?
| | Triage | 1 | 2019 | 250 | 0.120 |
Why?
| | Fatty Acids, Omega-3 | 1 | 2017 | 142 | 0.120 |
Why?
| | Autoimmunity | 2 | 2012 | 908 | 0.120 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2020 | 449 | 0.120 |
Why?
| | Interferon-beta | 1 | 2015 | 93 | 0.110 |
Why?
| | Double-Blind Method | 3 | 2026 | 1992 | 0.110 |
Why?
| | Epitopes | 3 | 2023 | 476 | 0.110 |
Why?
| | Wrist Injuries | 1 | 2014 | 23 | 0.110 |
Why?
| | Ligaments, Articular | 1 | 2014 | 54 | 0.110 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 2 | 2011 | 95 | 0.100 |
Why?
| | Peptides, Cyclic | 3 | 2026 | 273 | 0.100 |
Why?
| | Rituximab | 2 | 2011 | 204 | 0.090 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 1998 | 1111 | 0.090 |
Why?
| | Stress, Psychological | 1 | 2020 | 1124 | 0.090 |
Why?
| | Treatment Outcome | 6 | 2025 | 11216 | 0.090 |
Why?
| | Range of Motion, Articular | 1 | 2014 | 413 | 0.090 |
Why?
| | Bronchial Diseases | 1 | 2011 | 37 | 0.090 |
Why?
| | Middle Aged | 12 | 2026 | 34658 | 0.090 |
Why?
| | Muscle Strength | 1 | 2014 | 328 | 0.090 |
Why?
| | Adult | 10 | 2026 | 39319 | 0.080 |
Why?
| | Labor, Induced | 1 | 2011 | 36 | 0.080 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2015 | 1220 | 0.080 |
Why?
| | Humans | 21 | 2026 | 141284 | 0.080 |
Why?
| | Cyclophosphamide | 1 | 2011 | 257 | 0.080 |
Why?
| | Recovery of Function | 1 | 2014 | 684 | 0.080 |
Why?
| | Genes, Immunoglobulin | 1 | 1990 | 29 | 0.080 |
Why?
| | Immune Tolerance | 1 | 2012 | 373 | 0.080 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2011 | 129 | 0.080 |
Why?
| | Severity of Illness Index | 3 | 2025 | 2904 | 0.080 |
Why?
| | Female | 15 | 2026 | 75814 | 0.080 |
Why?
| | Health Fairs | 1 | 2009 | 10 | 0.080 |
Why?
| | Immunoglobulin Heavy Chains | 1 | 1990 | 85 | 0.080 |
Why?
| | Synovitis | 1 | 2009 | 36 | 0.080 |
Why?
| | Signal Transduction | 2 | 2021 | 5116 | 0.070 |
Why?
| | Male | 14 | 2026 | 70140 | 0.070 |
Why?
| | Drug Therapy, Combination | 1 | 2011 | 1043 | 0.070 |
Why?
| | Aspirin | 1 | 2011 | 388 | 0.070 |
Why?
| | Adrenal Cortex Hormones | 1 | 2011 | 501 | 0.070 |
Why?
| | Immunoglobulin M | 2 | 2022 | 284 | 0.060 |
Why?
| | Antibodies, Antinuclear | 1 | 2025 | 67 | 0.060 |
Why?
| | Biomarkers | 4 | 2021 | 4180 | 0.060 |
Why?
| | Lung Diseases | 1 | 2011 | 779 | 0.060 |
Why?
| | Aged | 6 | 2026 | 24836 | 0.060 |
Why?
| | Rheumatologists | 1 | 2023 | 15 | 0.050 |
Why?
| | Immunosuppressive Agents | 1 | 2008 | 855 | 0.050 |
Why?
| | Phosphorylation | 2 | 2021 | 1753 | 0.050 |
Why?
| | Complementarity Determining Regions | 1 | 2002 | 51 | 0.050 |
Why?
| | Immunoglobulin Isotypes | 1 | 2022 | 36 | 0.050 |
Why?
| | Risk Factors | 3 | 2023 | 10490 | 0.050 |
Why?
| | Incidence | 2 | 2020 | 2809 | 0.050 |
Why?
| | Colorado | 3 | 2020 | 4599 | 0.050 |
Why?
| | Clone Cells | 2 | 2002 | 267 | 0.050 |
Why?
| | Prospective Studies | 3 | 2022 | 7805 | 0.040 |
Why?
| | Leukocytes, Mononuclear | 2 | 2021 | 571 | 0.040 |
Why?
| | Mass Screening | 1 | 2009 | 1309 | 0.040 |
Why?
| | Abatacept | 1 | 2021 | 56 | 0.040 |
Why?
| | Immunoglobulin A | 1 | 2022 | 214 | 0.040 |
Why?
| | Antibodies, Monoclonal | 1 | 2008 | 1456 | 0.040 |
Why?
| | Young Adult | 4 | 2025 | 13727 | 0.040 |
Why?
| | Complement Activation | 1 | 2023 | 407 | 0.040 |
Why?
| | Joints | 2 | 2011 | 105 | 0.040 |
Why?
| | Sequence Analysis | 1 | 1998 | 35 | 0.040 |
Why?
| | Amino Acid Sequence | 2 | 2002 | 2146 | 0.040 |
Why?
| | Lymphocyte Activation | 1 | 2002 | 1136 | 0.040 |
Why?
| | Molecular Sequence Data | 2 | 2002 | 2911 | 0.030 |
Why?
| | Disease Progression | 1 | 2025 | 2808 | 0.030 |
Why?
| | Pregnancy | 1 | 2011 | 7035 | 0.030 |
Why?
| | HIV-1 | 1 | 2002 | 882 | 0.030 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2002 | 911 | 0.030 |
Why?
| | Aged, 80 and over | 2 | 2021 | 7948 | 0.030 |
Why?
| | Patient Selection | 1 | 2019 | 685 | 0.030 |
Why?
| | Base Sequence | 1 | 1998 | 2170 | 0.030 |
Why?
| | Odds Ratio | 1 | 2017 | 1057 | 0.030 |
Why?
| | Lunate Bone | 1 | 2014 | 10 | 0.030 |
Why?
| | Scaphoid Bone | 1 | 2014 | 17 | 0.030 |
Why?
| | Survival Analysis | 1 | 2017 | 1322 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2017 | 1268 | 0.030 |
Why?
| | Adolescent | 3 | 2025 | 22116 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2021 | 3577 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2020 | 2929 | 0.020 |
Why?
| | Syk Kinase | 1 | 2012 | 21 | 0.020 |
Why?
| | Immunoglobulin D | 1 | 2012 | 30 | 0.020 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2012 | 22 | 0.020 |
Why?
| | Tumor Necrosis Factor Receptor Superfamily, Member 7 | 1 | 2012 | 28 | 0.020 |
Why?
| | Clonal Anergy | 1 | 2012 | 52 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2023 | 5653 | 0.020 |
Why?
| | Arthrography | 1 | 2011 | 19 | 0.020 |
Why?
| | Receptors, Antigen, B-Cell | 1 | 2012 | 132 | 0.020 |
Why?
| | Antigens, CD19 | 1 | 2012 | 137 | 0.020 |
Why?
| | Risk Assessment | 1 | 2020 | 3522 | 0.020 |
Why?
| | Cell Differentiation | 1 | 1998 | 1983 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2015 | 1973 | 0.020 |
Why?
| | Retrospective Studies | 2 | 2022 | 16447 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2015 | 2069 | 0.020 |
Why?
| | Blotting, Northern | 1 | 1990 | 199 | 0.020 |
Why?
| | Immunoglobulin Variable Region | 1 | 1990 | 81 | 0.020 |
Why?
| | Cross Reactions | 1 | 1990 | 132 | 0.020 |
Why?
| | Hybridomas | 1 | 1990 | 233 | 0.020 |
Why?
| | Antibody Specificity | 1 | 1990 | 183 | 0.020 |
Why?
| | Databases, Factual | 1 | 2015 | 1449 | 0.020 |
Why?
| | Autoantigens | 1 | 2012 | 424 | 0.020 |
Why?
| | Molecular Weight | 1 | 1990 | 326 | 0.020 |
Why?
| | Mice, Mutant Strains | 1 | 1990 | 305 | 0.020 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2012 | 465 | 0.020 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2012 | 436 | 0.020 |
Why?
| | Seroepidemiologic Studies | 1 | 2009 | 170 | 0.020 |
Why?
| | Multigene Family | 1 | 1990 | 202 | 0.020 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2012 | 428 | 0.020 |
Why?
| | Community-Institutional Relations | 1 | 2009 | 102 | 0.020 |
Why?
| | Structure-Activity Relationship | 1 | 1990 | 569 | 0.020 |
Why?
| | Early Diagnosis | 1 | 2009 | 243 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2017 | 5222 | 0.020 |
Why?
| | Antigens, CD20 | 1 | 2008 | 35 | 0.020 |
Why?
| | Lymphocyte Count | 1 | 2008 | 167 | 0.020 |
Why?
| | Lymphocyte Depletion | 1 | 2008 | 136 | 0.020 |
Why?
| | HIV Infections | 1 | 2002 | 2981 | 0.020 |
Why?
| | Prognosis | 1 | 2015 | 4080 | 0.020 |
Why?
| | Registries | 1 | 2015 | 2205 | 0.020 |
Why?
| | Gene Expression | 1 | 1990 | 1490 | 0.010 |
Why?
| | United States | 1 | 2022 | 15298 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2014 | 2765 | 0.010 |
Why?
| | Genes, T-Cell Receptor beta | 1 | 2002 | 23 | 0.010 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2002 | 221 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2009 | 3345 | 0.010 |
Why?
| | Inflammation | 1 | 2011 | 2840 | 0.010 |
Why?
| | T-Lymphocyte Subsets | 1 | 2002 | 413 | 0.010 |
Why?
| | Sequence Analysis, DNA | 1 | 2002 | 815 | 0.010 |
Why?
| | Flow Cytometry | 1 | 2002 | 1182 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2009 | 5948 | 0.010 |
Why?
| | Mice | 1 | 1990 | 17969 | 0.010 |
Why?
| | Infant | 1 | 2002 | 9820 | 0.000 |
Why?
| | Animals | 1 | 1990 | 37328 | 0.000 |
Why?
| | Child, Preschool | 1 | 2002 | 11511 | 0.000 |
Why?
| | Child | 1 | 2002 | 22390 | 0.000 |
Why?
|
|
Striebich's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|